ClinicalTrials.gg
RecruitingNCT07577856DUET ENCORE-UCUpdated Nov 3, 2026

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of JNJ-78934804 and Guselkumab in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Recruiting at 318 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 3, 2026First sites in 7 new countries182 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Planned enrollment
6th of 28
644 · median 205
Started
2026
with 6 others
Phase 3
15 of 43
2 open now
Primary completion
2028-08
later than 10 of 20 live
Registered
38th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 10 of the 20 other live ones, and was the 38th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC.
  • Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy
  • An endoscopy subscore >=2 as obtained during central review of the screening video endoscopy
  • Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies

Exclusion criteria

Exclusion criteria:

  • Isolated proctitis (UC limited to the rectum only or to less than [\<] 20 centimeter [cm] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis
  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD
  • Has a history of or ongoing chronic or recurrent infectious disease
  • Has previously demonstrated inadequate initial response, loss of response, allergy, or intolerance to guselkumab or to golimumab
  • Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
644 participants (estimated)

Study arms

  • Experimental
    JNJ-78934804

    Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804

  • Active comparator
    Guselkumab

    Participants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804 · Drug: Guselkumab

Interventions

  • JNJ-78934804 will be administered subcutaneously.

    Also known as: JNJ-4804

  • Guselkumab will be administered subcutaneously.

    Also known as: TREMFYA

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission at Week 48

    Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants with Endoscopic Improvement at Week 48

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week 48

  2. Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48

    Corticosteroid-free (90 day) clinical remission is defined as clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.

    Time frame: At Week 48

  3. Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Histologic remission is defined as an absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system.

    Time frame: At Week 48

  4. Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48

    Fatigue response is defined as a greater than or equal to (\>=) 7- point reduction in the patient-reported outcomes measurement information system (PROMIS) fatigue short form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).

    Time frame: At Week 48

  5. Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0

    Percentage of participants with a SF subscore of 0 or 1 and RB subscore of 0 at three assessment time points of Week 12, Week 24, and Week 48 will be reported.

    Time frame: At Weeks 12, 24, and 48

  6. Percentage of Participants in Abdominal Pain Remission at Week 48

    Percentage of participants in abdominal pain remission at week 48 will be reported.

    Time frame: At Week 48

  7. Change From Baseline in Abdominal Pain Score at Week 48

    Change from baseline in abdominal pain score based on abdominal pain-numerical rating scale (AP-NRS) will be reported. NRS is 11 point (0 to 10) scoring system used to evaluate abdominal pain. The score of 0 represents "no pain" and the score of 10 represents "pain as bad as you can imagine", with greater scores indicating greater pain severity and intensity.

    Time frame: Baseline and Week 48

  8. Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48

    IBDQ response is defined as improvement from baseline in the total IBDQ score of \>= 16 points. The IBDQ is a 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).

    Time frame: At Week 48

  9. Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48

    PROMIS 29 MCS response is defined as a \>= 7-point improvement from baseline in PROMIS 29 MCS response at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.

    Time frame: At Week 48

  10. Percentage of Participants in Clinical Remission at Week 12

    Clinical remission is defined as an SF subscore of 0 or 1, RB subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week 12

  11. Percentage of Participants with Endoscopic Improvement at Week 12

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week 12

  12. Percentage of Participants with Mayo SF/RB Response at Week 2

    Mayo SF/RB response is defined as a decrease from baseline in the sum of the SF and the RB subscores by \>=30 percent (%) and \>= 1 point, with either a \>= 1 point decrease from baseline in the RB subscore or an RB subscore of 0 or 1.

    Time frame: At Week 2

  13. Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to approximately 3 years

07

Study locations

318 of 318 sites recruiting

Showing the first 100 of 318 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2028, 26 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 26 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
May 23, 2026
Primary completionEst.
Aug 11, 2028
CompletionEst.
Oct 16, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
182 sites added, 34 sites removed — first sites in Austria, Greece, Hungary, Italy, Romania and 2 more
All 7 countries

Austria, Greece, Hungary, Italy, Romania, Switzerland, Mexico

Show 182 added (17 China, 13 France, 12 Germany, 11 United States, 11 Italy, 11 United Kingdom, 10 Japan, 9 Poland, 8 Belgium, 6 Hungary, 6 Romania, 5 Australia, 5 Brazil, 5 Bulgaria, 5 Czechia, 5 Greece, 5 South Korea, 4 Austria, 4 Spain, 4 Mexico, 3 India, 3 Netherlands, 3 Norway, 3 Portugal, 3 Switzerland, 3 Taiwan, 3 Israel, 2 Argentina, 2 Turkey (Türkiye), 1 Slovakia)
  • GIA Metairie · Metairie, United States
  • GIA Kansas City · Lee's Summit, United States
  • University of North Carolina Hospital · Chapel Hill, United States
  • Frontier Clinical Research · Uniontown, United States
  • Hospital Provincial del Centenario · Rosario, Argentina
  • Macquarie University · Macquarie University, Australia
  • Kepler Universitatsklinikum GmbH · Linz, Austria
  • Krankenhaus der Barmherzigen Brüder · Vienna, Austria
  • Klinikum Wels Grieskirchen · Wels, Austria
  • Cliniques Universitaires Saint Luc · Brussels, Belgium
  • CHC MontLegia · Liège, Belgium
  • CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda · Jaú, Brazil
  • Complexo Hospitalar de Niteroi · Niterói, Brazil
  • Solare Trials · São Paulo, Brazil
  • St Ivan Rilski University Multiprofile Hospital For Active Treatment · Sofia, Bulgaria
  • DCC Convex EOOD · Sofia, Bulgaria
  • Acibadem City Clinic - Oncology Center · Sofia, Bulgaria
  • Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD · Varna, Bulgaria
  • China Japan Friendship Hospital · Beijing, China
  • The First People's Hospital of Foshan · Foshan, China
  • The Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine · Hangzhou, China
  • The First Affiliated Hospital of Anhui Medical University · Hefei, China
  • Jinhua municipal central hospital · Jinhua, China
  • Lanzhou University Second Hospital · Lanzhou, China
  • Taihe Hospital · Shiyan, China
  • Second Affiliated Hospital, SooChow University · Suzhou, China
  • Zhongshan Hospital, Xiamen University · Xiamen, China
  • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, China
  • Affiliated Hospital of Zunyi Medical University · Zunyi, China
  • …and 152 more on the registry record
Show 34 removed
  • Michigan Center of Medical Research · Farmington Hills, United States
  • GEDYT · AAI, Argentina
  • The Melbourne Gut Clinic Epworth Hospital · East Melbourne, Australia
  • SA Gastrointestinal Services · Kurralta Park, Australia
  • Macquarie University · Macquarie University, Australia
  • John Hunter Hospital · New Lambton Heights, Australia
  • AZ Sint-Lucas · Bruges, Belgium
  • ULB Erasme Ziekenhuis · Brussels, Belgium
  • UZ Brussel · Brussels, Belgium
  • Cliniques Universitaires Saint Luc · Brussels, Belgium
  • AZ Maria Middelares · Ghent, Belgium
  • Ghent University Hospital · Ghent, Belgium
  • Gastroenterologie, s.r.o., Hradec Kralove · Hradec Kralova, Czechia
  • CHRU de Nancy - Hopitaux de Brabois · Vandœuvre-lès-Nancy, France
  • Gastroenterologische Spezialpraxis - Berlin-Karlshorst · Karlshorst, Germany
  • Sushruta Multispecialty Hospital and Research Centre · Hubballi, India
  • P D Hinduja National Hospital and Medical Research Center · Mumbai, India
  • Wolfson Medical Center · Holon, Israel
  • Shaare Zedek Medical Center · Jerusalem, Israel
  • Meir Medical Center · Kfar Saba, Israel
  • Ospedale Sacro Cuore Negrar-Verona · Negrar Verona, Italy
  • Azienda Ospedaliera San Camillo-Forlanini · Roma, Italy
  • Fondazione Policlinico Universitario A Gemelli IRCCS · Roma, Italy
  • Fatebenefratelli Isola Tiberina - Gemelli Isola · Roma, Italy
  • National Hospital Organization Mito Medical Center · Higashi-Ibaraki, Japan
  • Hyogo Medical University Hospital · Nishinomiya Shi, Japan
  • Center Hospital of the National Center for Global Health and Medicine · Shinjuku Ku, Japan
  • Tokyo Metropolitan Bokutoh Hospital · Sumida Ku, Japan
  • Akershus Universitetssykehus · Lorenskog, Norway
  • Korea University Ansan Hospital · Ansan-si, South Korea
  • …and 4 more on the registry record
across 2 updates, Oct 13, 2026 – Nov 3, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange From Baseline in Abdominal Pain Score at Week 48Time frame: Baseline and Week 48
Oct 13, 2026
Show all 2 updates
  1. Nov 3, 2026
    73 sites added, 34 sites removed — first site in Mexico
    Show 73 added (7 United States, 6 Belgium, 6 United Kingdom, 5 China, 5 Japan, 4 Australia, 4 Germany, 4 Italy, 4 Mexico, 3 Czechia, 3 France, 3 Israel, 3 South Korea, 2 Brazil, 2 India, 2 Switzerland, 2 Turkey (Türkiye), 1 Argentina, 1 Austria, 1 Bulgaria, 1 Greece, 1 Norway, 1 Poland, 1 Romania, 1 Spain)
    • Mayo Clinic · Scottsdale, United States
    • GIA Sun City · Sun City, United States
    • Endoscopic Research Inc · Orlando, United States
    • Michigan Center of Medical Research · Farmington Hill, United States
    • Palmetto Primary and Specialty Care Physicians, Charleston · Summerville, United States
    • GIA Webster · Webster, United States
    • GIA Richmond · Richmond, United States
    • GEDYT · Famailla, Argentina
    • SA Gastrointestinal Services · Kurraba Point, Australia
    • Macquarie University · Macquarie Island, Australia
    • John Hunter Hospital · New Lambton, Australia
    • The Melbourne Gut Clinic Epworth Hospital · West Melbourne, Australia
    • LKH - Universitätsklinikum der PMU Salzburg · Salzburg, Austria
    • AZ Sint-Lucas · Brugge (Bruges), Belgium
    • UZ Brussel · Brussel (Bruxelles), Belgium
    • Cliniques Universitaires Saint Luc · Brussel (Bruxelles), Belgium
    • AZ Maria Middelares · Gent (Ghent), Belgium
    • Ghent University Hospital · Gent (Ghent), Belgium
    • ULB Erasme Ziekenhuis · Koekelberg/Brussel (Bruxelles), Belgium
    • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu · Botucatu, Brazil
    • Liga Norte Riograndense Contra O Cancer · Natal, Brazil
    • University Multiprofile Hospital for Active Treatment - Tsaritsa Yoanna - ISUL, EAD · Sofia, Bulgaria
    • Peking Union Medical College Hospital · Beijing, China
    • West China Hospital Si Chuan University · Chengdu, China
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
    • The first affiliated hospital of Henan University of science and technology · Luoyang, China
    • Ruijin Hospital Shanghai Jiao Tong University · Shanghai, China
    • SurGal Clinic · Brno, Czechia
    • Gastroenterologie, s.r.o., Hradec Kralove · Hradec Králové, Czechia
    • IKEM · Prague, Czechia
    • …and 43 more on the registry record
    Show 34 removed
    • Michigan Center of Medical Research · Farmington Hills, United States
    • GEDYT · AAI, Argentina
    • The Melbourne Gut Clinic Epworth Hospital · East Melbourne, Australia
    • SA Gastrointestinal Services · Kurralta Park, Australia
    • Macquarie University · Macquarie University, Australia
    • John Hunter Hospital · New Lambton Heights, Australia
    • AZ Sint-Lucas · Bruges, Belgium
    • ULB Erasme Ziekenhuis · Brussels, Belgium
    • UZ Brussel · Brussels, Belgium
    • Cliniques Universitaires Saint Luc · Brussels, Belgium
    • AZ Maria Middelares · Ghent, Belgium
    • Ghent University Hospital · Ghent, Belgium
    • Gastroenterologie, s.r.o., Hradec Kralove · Hradec Kralova, Czechia
    • CHRU de Nancy - Hopitaux de Brabois · Vandœuvre-lès-Nancy, France
    • Gastroenterologische Spezialpraxis - Berlin-Karlshorst · Karlshorst, Germany
    • Sushruta Multispecialty Hospital and Research Centre · Hubballi, India
    • P D Hinduja National Hospital and Medical Research Center · Mumbai, India
    • Wolfson Medical Center · Holon, Israel
    • Shaare Zedek Medical Center · Jerusalem, Israel
    • Meir Medical Center · Kfar Saba, Israel
    • Ospedale Sacro Cuore Negrar-Verona · Negrar Verona, Italy
    • Azienda Ospedaliera San Camillo-Forlanini · Roma, Italy
    • Fondazione Policlinico Universitario A Gemelli IRCCS · Roma, Italy
    • Fatebenefratelli Isola Tiberina - Gemelli Isola · Roma, Italy
    • National Hospital Organization Mito Medical Center · Higashi-Ibaraki, Japan
    • Hyogo Medical University Hospital · Nishinomiya Shi, Japan
    • Center Hospital of the National Center for Global Health and Medicine · Shinjuku Ku, Japan
    • Tokyo Metropolitan Bokutoh Hospital · Sumida Ku, Japan
    • Akershus Universitetssykehus · Lorenskog, Norway
    • Korea University Ansan Hospital · Ansan-si, South Korea
    • …and 4 more on the registry record
    + 1 other change: verification date
  2. Oct 13, 2026
    109 sites added — first sites in Austria, Greece, Hungary, Italy, Romania and 1 more
    All 6 countries

    Austria, Greece, Hungary, Italy, Romania, Switzerland

    Show 109 added (12 China, 10 France, 8 Germany, 8 Poland, 7 Italy, 6 Hungary, 5 Japan, 5 Romania, 5 United Kingdom, 4 United States, 4 Bulgaria, 4 Greece, 3 Austria, 3 Brazil, 3 Netherlands, 3 Portugal, 3 Spain, 3 Taiwan, 2 Belgium, 2 Czechia, 2 Norway, 2 South Korea, 1 Argentina, 1 Australia, 1 India, 1 Slovakia, 1 Switzerland)
    • GIA Metairie · Metairie, United States
    • GIA Kansas City · Lee's Summit, United States
    • University of North Carolina Hospital · Chapel Hill, United States
    • Frontier Clinical Research · Uniontown, United States
    • Hospital Provincial del Centenario · Rosario, Argentina
    • Macquarie University · Macquarie University, Australia
    • Kepler Universitatsklinikum GmbH · Linz, Austria
    • Krankenhaus der Barmherzigen Brüder · Vienna, Austria
    • Klinikum Wels Grieskirchen · Wels, Austria
    • Cliniques Universitaires Saint Luc · Brussels, Belgium
    • CHC MontLegia · Liège, Belgium
    • CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda · Jaú, Brazil
    • Complexo Hospitalar de Niteroi · Niterói, Brazil
    • Solare Trials · São Paulo, Brazil
    • St Ivan Rilski University Multiprofile Hospital For Active Treatment · Sofia, Bulgaria
    • DCC Convex EOOD · Sofia, Bulgaria
    • Acibadem City Clinic - Oncology Center · Sofia, Bulgaria
    • Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD · Varna, Bulgaria
    • China Japan Friendship Hospital · Beijing, China
    • The First People's Hospital of Foshan · Foshan, China
    • The Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
    • Sir Run Run Shaw Hospital Zhejiang University School of Medicine · Hangzhou, China
    • The First Affiliated Hospital of Anhui Medical University · Hefei, China
    • Jinhua municipal central hospital · Jinhua, China
    • Lanzhou University Second Hospital · Lanzhou, China
    • Taihe Hospital · Shiyan, China
    • Second Affiliated Hospital, SooChow University · Suzhou, China
    • Zhongshan Hospital, Xiamen University · Xiamen, China
    • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, China
    • Affiliated Hospital of Zunyi Medical University · Zunyi, China
    • …and 79 more on the registry record
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange From Baseline in Abdominal Pain Score at Week 48Time frame: Baseline and Week 48
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577856
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 23, 2026
Primary completion
Aug 11, 2028 (estimated)
Completion
Oct 16, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-78934804

Start the discussion